

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

BIOADAPTIVES, INC. CONSOLIDATED BALANCE SHEETS

	September 30, 2017	December 31, 2016
ASSETS		
Current Assets:		
Cash	\$ 644	\$ 7,635
Inventory	133,456	135,274
Marketable securities	2,421	3,648
Total Current Assets	<u>136,521</u>	<u>146,557</u>
Furniture and Fixtures, net	-	-
TOTAL ASSETS	\$ <u>136,521</u>	\$ <u>146,557</u>
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current Liabilities:		
Accounts payable	58	2,600
Accrued liabilities - related party	56,861	43,361
Advance from Ferris Holding, Inc. - related party	270,221	276,956
Total Current Liabilities	<u>327,140</u>	<u>322,917</u>
Total Liabilities	<u>327,140</u>	<u>322,917</u>
Stockholders' Deficit:		
Preferred stock, (\$.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)	-	-
Common stock (\$.0001 par value, 100,000,000 shares authorized; 14,180,456 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively)	1,419	1,419
Additional paid-in capital	2,877,786	2,872,604
Accumulated other comprehensive loss	(59,118)	(57,891)
Accumulated deficit	<u>(3,010,706)</u>	<u>(2,992,492)</u>
Total Stockholders' Deficit	<u>(190,619)</u>	<u>(176,360)</u>
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$ <u>136,521</u>	\$ <u>146,557</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

BIOADAPTIVES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2017	2016	2017	2016
Revenues	\$ 1,674	\$ 11,944	\$ 3,735	\$ 11,944
Cost of revenue	<u>812</u>	<u>5,834</u>	<u>1,818</u>	<u>5,834</u>
Gross Profit	862	6,110	1,917	6,110
Operating Expenses				
Depreciation	-	132	-	395
General and administrative	5,373	29,951	19,913	130,543
Professional fees	<u>-</u>	<u>2,340</u>	<u>218</u>	<u>15,614</u>
Total Operating Expenses	5,373	32,423	20,131	146,552
Operating Loss	(4,511)	(26,313)	(18,214)	(140,442)
Net Loss	<u>\$ (4,511)</u>	<u>\$ (26,313)</u>	<u>\$ (18,214)</u>	<u>\$ (140,442)</u>
Other Comprehensive Loss, net of tax				
Unrealized gain (loss) on marketable securities	<u>211</u>	<u>53</u>	<u>(1,227)</u>	<u>(1,956)</u>
Other Comprehensive Loss	211	53	(1,227)	(1,956)
Comprehensive Loss	<u>(4,300)</u>	<u>(26,260)</u>	<u>(19,441)</u>	<u>(142,398)</u>
Net Loss Per Common Share: Basic and Diluted	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.01)</u>
Weighted Average Number of Common Shares Outstanding: Basic and Diluted	<u>14,180,456</u>	<u>14,180,456</u>	<u>14,180,456</u>	<u>13,943,348</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

BIOADAPTIVES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Nine Months Ended September 30,	
	2017	2016
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$ (18,214)	\$ (140,442)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	-	395
Stock-based compensation - related party	5,182	41,307
Changes in operating assets and liabilities:		
Inventory	1,818	5,434
Accounts payable	(2,542)	89,693
Accrued liabilities – related party	13,500	13,500
Net Cash Provided By (Used In) Operating Activities	(256)	9,887
CASH FLOWS FROM FINANCING ACTIVITIES		
Advances from related party	1,500	4,913
Payment on advances from related party	(8,235)	(2,950)
Net Cash Provided By (Used In) Financing Activities	(6,735)	1,963
Net change in cash	(6,991)	11,850
Cash at beginning of period	7,635	99
Cash at end of period	\$ 644	\$ 11,949
SUPPLEMENTAL CASH FLOW INFORMATION:		
Cash paid for income taxes	\$ -	\$ -
Cash paid for interest	\$ -	\$ -
NON CASH INVESTING AND FINANCING ACTIVITIES		
Settlement of liabilities by related party	\$ -	\$ 111,662
Unrealized loss on investments in marketable securities	\$ 1,227	\$ 1,956
Purchase of inventory by common shares	\$ -	\$ 144,402

The accompanying notes are an integral part of these unaudited consolidated financial statements.

BioAdaptives, Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Nine Months Ended September 30, 2017
(Unaudited)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business – BioAdaptives, Inc. (formerly known as APEX 8 Inc.) (“BioAdaptives”, “Company”) was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages.

On September 11, 2013, BioAdaptives incorporated Blenders Choice Inc (“Blenders”) in Nevada. Blenders is a 100% owned subsidiary and was created as a separate sales and marketing organization. BioAdaptives has elected to manage its sales through independent distributors and has suspended operations of Blenders Choice.

On September 1, 2014, the Company entered into a License Agreement (“Agreement”) with Ferris Holding, Inc. (“Ferris”). The Agreement gives the Company the right to use Ferris’s proprietary processes and trade secrets, including its stem cell enhancement products. In consideration for these rights, the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

On September 1, 2014, the Company entered into a Sub-License Agreement (“Sub-License”) with Essence International, Ltd. (“Essence”). The Sub-License gives Essence the right to use proprietary processes and trade secrets, including its stem cell enhancement products which were obtained by the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

2. SUMMARY OF SIGNIFICANT POLICIES

Investment Securities - Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.

In accordance with Accounting Standards Codification (“ASC”) 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the

entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.

Fair value of financial instruments – As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 (“ASC 820-10”), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:

- Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
- Level 2 Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
- Level 3 Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Pursuant to ASC 825, Financial Instruments, the fair value of cash, marketable securities and stock based compensation is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

Assets measured at fair value on a recurring basis were presented on the Company’s balance sheet as of September 30, 2017.

Fair Value Measurements as of September 30, 2017 Using:

	Total Carrying Value as of September 30, 2017	Quoted Market Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<u>Assets:</u>				
Equity Securities	\$ 2,421	\$ 2,421	\$ -	\$ -
Total	\$ 2,421	\$ 2,421	\$ -	\$ -

Equity securities at September 30, 2017, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of \$2,421 (\$0.0229 per share).

Inventory

Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out (“FIFO”) method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at September 30, 2017, the Company determined that no reserve was required.

3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of \$3,010,706 as of September 30, 2017. The

Company requires capital for its contemplated operational and marketing activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

4. STOCKHOLDERS' EQUITY

Preferred Stock – The Company is authorized to issue 5,000,000 shares of \$.0001 par value preferred stock. As of September 30, 2017 and December 31, 2016, no shares of preferred stock had been issued.

Common Stock – The Company is authorized to issue 100,000,000 shares of \$.0001 par value common stock. As of September 30, 2017 and December 31, 2016, there were 14,180,456 shares of the Company's common stock issued and outstanding.

In the year ended December 31, 2015, the Company issued 100,000 shares of common stock to its chief executive officer, Christopher G. Hall, as compensation for two year of services to be performed pursuant to an employment agreement dated February 6, 2015. The Company valued the 100,000 shares of common stock on the date of the agreement, \$1.10 per share, which resulted in a total consideration of \$110,050 which will be expensed throughout the two year term of the employment agreement. For the nine months ended September 30, 2017 and 2016, the Company expensed \$5,182 and \$13,719, respectively.

5. RELATED PARTY TRANSACTIONS

Advances from Ferris Holding, Inc., the controlling shareholder of the Company, are non-interest bearing, unsecured and due on demand. During the six months ended September 30, 2017, the Company received cash advance of \$1,500 from Ferris Holding, Inc and repaid cash of \$8,235 to Ferris Holding, Inc. As of September 30, 2017, and December 31, 2016, the Company had advances from Ferris Holdings, Inc. – related party balance of \$270,895 and \$276,956, respectively.

On February 6, 2015, the Company entered into a two (2) year employment agreement with its chief executive officer, Christopher G. Hall, whereby the Company issued 100,000 shares of restricted common stock as compensation for two (2) years of executive services to be performed. The shares were valued at the closing share price of \$1.10 on the date of the agreement. This resulted in compensation expense of \$110,050 being amortized over the two (2) year term of the employment agreement. Compensation expense of \$5,182 was amortized for nine months ended September 30, 2017.

On June 1, 2014, the Company entered into a rental agreement with Ferris for the corporate office. Monthly rent is \$1,500. The term of the lease is month to month. As of September 30, 2017 and December 31, 2016, the Company has a rent payable due to Ferris in the amount of \$56,861 and \$43,361, respectively, which is included in our accrued liabilities – related party balance in our consolidated balance sheets.

6. SUBSEQUENT EVENTS

On October 3, 2017, the Company sold all current inventory to Ferris Holding, Inc for \$133,472. The amount was paid by reducing due to related party.

On October 3, 2017, the Company issued 1,197,806 shares of common stock to repay all remaining debt owed to Ferris Holding Inc of \$203,627.

On October 3, 2017, the Company issued 200,000 shares of common to unrelated parties stock for service.